More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/PP2 [172889-27-9]
Chemical Structure
Chemical Structure
Chemical Structure

PP2 [172889-27-9]

Research Use Only
AG-CR1-3563
AdipoGen Life Sciences
CAS Number172889-27-9
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight301.8
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    PP2 [172889-27-9]
  • Delivery Days Customer
    10
  • CAS Number
    172889-27-9
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C15H16ClN5
  • Molecular Weight
    301.8
  • Scientific Description
    Chemical. CAS: 172889-27-9. Formula: C15H16ClN5. MW: 301.8. Highly potent and selective Scr family tyrosine kinase inhibitor. Reduces cancer metastasis. Apoptotic. Antitumor compound. RIP2 inhbitor. Blocks TGF-beta-mediated cellular responses. Autophagy modulator. - Highly potent and selective Scr family tyrosine kinase inhibitor [1, 4, 6]. Reduces cancer metastasis [2]. Apoptotic [5]. Antitumor compound [2, 3, 5]. RIP2 inhbitor [6]. Blocks TGF-beta-mediated cellular responses [7]. Autophagy modulator [8].
  • SMILES
    CC(C)(C)N1N=C(C2=C1N=CN=C2N)C1=CC=C(Cl)C=C1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation: J.H. Hanke, et al.; J. Biol. Chem. 271, 695 (1996)
  • Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis: J.S. Nam, et al.; Clin. Cancer Res. 8, 2430 (2002)
  • Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2): F. Carlomagno, et al.; J. Clin. Endocrinol. Metab. 88, 1897 (2003)
  • The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)
  • Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia: M. Lee, et al.; J. Cell Biochem. 93, 629 (2004)
  • The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007)
  • The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors: H. Ungefroren, et al.; Curr. Cancer Drug Targets 11, 524 (2011)
  • Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2: J.H. Ahn & M. Lee; Cancer Lett. 310, 188 (2011)